# A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause

> **NCT04234204** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma China, Inc.** · enrollment: 302 (actual)

## Conditions studied

- Hot Flashes

## Interventions

- **DRUG:** Fezolinetant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04234204
- **Lead sponsor:** Astellas Pharma China, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-17
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-04-20
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04234204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04234204, "A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04234204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*